1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again

 
• By Alaric DeArment

The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.

OS data from Gilead's TROPiCS-02 trial exceeded the expectations of many investors • Source: Shutterstock

Gilead Sciences, Inc.’s anti-TROP2 antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) beat expectations as data from the Phase III TROPiCS-02 study showed a statistically significant improvement on overall survival among patients with HR-positive/HER2-negative metastatic breast cancer. It also compared more favorably to data for the drug’s top competitor, AstraZeneca plc and Daiichi Sankyo Co., Ltd.’s HER2-targeting Enhertu, than previously thought.

The company released the data on 7 September, which it plans to present at the European Society for Medical Oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.